Sigma Planning Corp Has $1.27 Million Stock Position in TG Therapeutics, Inc. $TGTX

Sigma Planning Corp raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 35,227 shares of the biopharmaceutical company’s stock after acquiring an additional 3,472 shares during the quarter. Sigma Planning Corp’s holdings in TG Therapeutics were worth $1,268,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC increased its position in shares of TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock worth $898,000 after buying an additional 8,338 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of TG Therapeutics during the first quarter worth $226,000. Strs Ohio acquired a new stake in shares of TG Therapeutics during the first quarter worth $785,000. KLP Kapitalforvaltning AS increased its position in shares of TG Therapeutics by 7.7% during the second quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock worth $1,108,000 after buying an additional 2,200 shares during the period. Finally, Yorktown Management & Research Co Inc acquired a new stake in shares of TG Therapeutics during the second quarter worth $383,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 0.7%

TG Therapeutics stock opened at $34.04 on Thursday. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 92.00 and a beta of 1.97. The firm’s fifty day moving average price is $33.77 and its two-hundred day moving average price is $34.74. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. During the same period last year, the firm earned $0.02 earnings per share. The business’s quarterly revenue was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.64% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the topic of several research analyst reports. HC Wainwright initiated coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.25.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.